CRL vs MRK: fair value comparison
Charles River Laboratories International, Inc. and Merck & Co., Inc. · Updated 2026-09-06
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, MRK currently sits closer to the top of our discount ranking.
| CRL | MRK | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $288.50 | $150.33 |
| 12-month range | $165.78–$282.34 | $82.49–$149.86 |
| Sector rank | #99 of 113 Healthcare | #95 of 113 Healthcare |
| Quality grade | C | C |
| Leverage | Moderate | Moderate |
| Margin trend | Contracting | Expanding |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Overvalued | Fairly Valued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: CRL fair value analysis · MRK fair value analysis